Restricted accessOtherFirst published online 2010-3
Prevention of Tuberculosis Infections in Patients Considered for Anti-TNF-α Therapy: Practical Application of National Psoriasis Foundation Consensus Statement
Tumor necrosis factor inhibitors have been linked to increased Mycobacterium tuberculosis infections. In order to standardize treatment and minimize risks to patients, the National Psoriasis Foundation (NPF) issued a consensus statement on patient management regarding this issue, including advice on when to use the FDA-approved QuantiFERON® TB Gold screening test. The evidence-based guidelines developed in the Psoriasis Foundation statement are summarized in a practical clinical algorithm, which we have applied to the management of a patient with severe psoriasis. Proper utilization of this algorithm clarifies the risks and benefits balance of using these biologics. In general, the tumor necrosis factor-alpha (TNF-α) inhibitors possess impressive rates of efficacy in the treatment of psoriasis and relatively fewer adverse effects when compared with other systemic immunosuppressants.
DohertyS.D., Van VoorheesA., Lebwohlmg, KormanN.J., YoungM.S., HsuS.National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol.2008 Aug; 59(2): 209–17. Epub 2008 May 15.
KeaneJ., GershonS., WiseR.P., Mirabile-LevensE., KasznicaJ., SchwietermanW.D.Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med.2001; 345: 1098–104.
7.
TaylorZ., NolanC.M., BlumbergH.M., American Thoracic Society, Centers for Disease Control, and Prevention, Infectious Diseases Society of America. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep2005; 54: 1–81.
8.
DenisM.Tumor necrosis factor and granulocyte macro phage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol.1991 Apr; 49(4): 380–7.
9.
KaplanG., FreedmanV.H.The role of cytokines in the immune response to tuberculosis. Res Immunol.1996; 147: 565–72.
10.
European Medicine Agency (EMEA). Summary of product characteristics: Enbrel [online]. Available from URL: http://www.emea.eu.int.
11.
Sociedad Espanola de Rheumatologia. Spanish registry for adverse events of biological therapies in rheumatic diseases [online]. Available from URL: http://biobadaser.ser.es.
12.
KeaneJ., GershonS., WiseR.P.Tuberculosis associated with infliximab, a tumor necrosis alpha-neutralizing agent. N Engl J Med.2001 Oct 11; 345(15): 1098–104.
SchiffM.H., BurmesterG.R., KentJ.D., PanganA.L., KupperH., FitzpatrickS.B.Safety analyses of adalimumab (HUMIRA) in global clinical trials and US post-marketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis.2006; 65: 889–94.
15.
HernandezC., CetnerA.S., JordanJ.E., PuangsuvanS.N., RobinsonJ.K.Tuberculosis in the age of biologic therapy. J Am Acad Dermatol.2008 Sep; 59(3): 363–80.
16.
American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med.2000; 161: 1376–95.
17.
WinthropK.L.Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol.2006; 2: 602–10.
HatemiG., MelikogluM., FreskoI., MasatliogluS., TascilarK., YaziciH.Infliximab does not suppress the tuberculin skin test (purified protein derivative). J Rheumatol.2007 Mar; 34(3): 474–80.
20.
WinthropK.L., SiegelJ.N., JerebJ., TaylorZ., IademarcoM.F.Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum.2005; 52: 2968–74.
21.
PaiM., RileyL.W., ColfordJMJr.Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis.2004 Dec; 4(12): 761–76.
22.
SellamJ., HamdiH., RoyC., BaronG., LemannM., PuéchalX., BrebanM., BerenbaumF., HumbertM., WeldinghK., SalmonD., RavaudP., EmilieD., MarietteX; RATIO (Research Axed on Tolerance of Biotherapies) Study Group. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis.2007 Dec; 66(12): 1610–5.
23.
American Thoracic Society, CDC. Targeted testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med.2000; 161: S221–47.
24.
Centers for Disease Control, and Prevention (CDC); American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection – United States, 2003. MMWR Morb Mortal Wkly Rep.2003 Aug 8; 52(31): 735–9.
25.
CarmonaL., Gómez-ReinoJ.J., Rodríguez-ValverdeV., MonteroD., Pascual-GómezE., MolaE.M., CarreñoL., FigueroaM; BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum.2005 Jun; 52(6): 1766–72.
26.
ListingJ., StrangfeldA., KaryS., RauR., von HinueberU., Stoyanova-ScholzM., Gromnica-IhleE., AntoniC., HerzerP., KekowJ., SchneiderM., ZinkA.Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum.2005 Nov; 52(11): 3403–12.
27.
SmithJ.D., KnoxJ.M.Psoriasis, methotrexate and tuberculosis. Br J Dermatol.1971; 84: 590–3.
28.
di GirolamoC., PapponeN., MelilloE., RengoC., GiulianoF., MelilloG.Cavitary lung tuberculosis in a rheumatoid arthritis patient treated with low-dose methotrexate and steroid pulse therapy. Br J Rheumatol.1998 Oct; 37(10): 1136–7.
29.
BinyminK., CooperR.G.Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford).2001 Mar; 40(3): 341–2.
30.
LebwohlM., BagelJ., GelfandJ.M., GladmanD., GordonK.B., HsuS., KalbR.E., KimballA.B., KormanN.J., KruegerG.G., MeaseP., MorisonW.L., PallerA., PariserD.M., RitchlinC., StroberB., Van VoorheesA., WeinsteinG.D., YoungM., HornE.J.From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol.2008; 58(1): 94–105.
